Radiofrequency ablation for hepatocellular carcinoma

International Journal of Hyperthermia

Volumn 29, Issue 6, 2013, Pages 558-568

  Nishikawa, Hiroki ^a   Kimura, Toru ^a   Kita, Ryuichi ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Radiofrequency ablation; Treatment

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; PERFLUBUTANE; SHU 508; SORAFENIB;

ADJUVANT THERAPY; ASCITES; BILOMA; CANCER SURGERY; CHEMOEMBOLIZATION; CHOLESTASIS; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DIGESTIVE SYSTEM PERFORATION; ECHOGRAPHY; HEMATOTHORAX; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FAILURE; LONG TERM CARE; MICROWAVE THERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PNEUMOTHORAX; PORTAL VEIN THROMBOSIS; POSTOPERATIVE HEMORRHAGE; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT INDICATION;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HUMANS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 84882749455     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2013.821528     Document Type: Review

References (124)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127: S5-16 (Pubitemid 39423365)
2. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: Present and future. Clin Liver Dis 2011;15: 223-43
3. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011;100:22-9
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73
5. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012;56:S75-87
6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365: 1118-27
7. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol 1993;9:298-304 (Pubitemid 23216368)
8. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surgery 2009;249:195-202
9. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol 2013;42: 151-60
10. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9 (Pubitemid 26079803)
11. Takayama T, Makuuchi M, Hasegawa K. Single HCC smaller than cm: Surgery or ablatioñ Surgeon's perspective. J Hepatobiliary Pancreat Sci 2010;17:422-4
12. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796-802 (Pubitemid 39030937)
13. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, et al. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg 2007;204:1-6 (Pubitemid 44960045)
14. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Sakaomoto A, et al. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 2012;41:903-9
15. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9 (Pubitemid 44142456)
16. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994;74: 817-25 (Pubitemid 24237460)
17. Hinshaw JL, Lee Jr FT. Cryoablation for liver cancer. Tech Vasc Interv Radiol 2007;10:47-57 (Pubitemid 350008080)
18. Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1:73-81
19. Livraghi T, Vettori C. Percutaneous ethanol injection therapy of hepatoma. Cardiovasc Intervent Radiol 1990;13:146-52 (Pubitemid 20269113)
20. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228: 235-40 (Pubitemid 36736097)
21. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma5or 4 cm. Gastroenterology 2004;127: 1714-23
22. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-6
23. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-30 (Pubitemid 41002049)
24. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008;43:727-35 (Pubitemid 351868714)
25. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8 (Pubitemid 43327762)
26. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903-12
27. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57: 794-802
28. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50:305-8
29. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/ interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8 (Pubitemid 41631953)
30. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007;25:3069-75
31. Edeline J, Raoul JL, Vauleon E, Guillygomac'h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J Gastroenterol 2009;15:713-6
32. Hiroki Nishikawa, Yukio Osaki, Ryuichi Kita, Toru Kimura. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan. Cancers 2012;4:165-83
33. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
34. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
35. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: Clinical practice. Int J Clin Oncol 2010;15:242-55
36. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, et al. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6
37. Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, et al. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: A case report. Oncology 2011;81:152-7
38. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381-91
39. Kurokohchi K, Masaki T, Himoto T, Deguchi A, Nakai S, Yoneyama H, et al. Successful laparoscopic radiofrequency ablation of hepatocellular carcinoma adhered to the mesentery after transcatheter arterial embolization. Oncol Rep 2005;13:65-8
40. Ishikawa T, Kohno T, Shibayama T, Fukushima Y, Obi S, Teratani T, et al. Thoracoscopic thermal ablation therapy for hepatocellular carcinoma located beneath the diaphragm. Endoscopy 2001;33:697-702 (Pubitemid 32725163)
41. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011;98:1210-24
42. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: Updated review in 2010. Oncology 2010;78:113-24
43. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011;11:143
44. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, et al. Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma. Anticancer Res 2012;32:5059-65
45. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: Clinical outcome and safety in elderly patients. J Gastrointestin Liver Dis 2012;21:397-405
46. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667-85
47. Hasegawa K, Kokudo N, Makuuchi S, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. J Hepatol 2013;58:724-9
48. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36 (Pubitemid 43112690)
49. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-77
50. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, et al. Radiofrequency ablation for hepatocellular carcinoma: The relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2012. doi 10.1007/s00535-012-0690-0
51. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002;89:1206-22 (Pubitemid 36002536)
52. Ikeda M, Okada S, Ueno H, Okusaka T, Kuriyama H. Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: A comparative study. Jpn J Clin Oncol 2001;31:322-6 (Pubitemid 32791460)
53. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. J Hepatol 2010;52:380-8
54. Kudo M. Local ablation therapy for hepatocellular carcinoma: Current status and future perspectives. J Gastroenterol 2004;39: 205-14 (Pubitemid 38519424)
55. Kasugai H, Osaki Y, Oka H, Kudo M, Seki T; Osaka Liver Cancer Study Group. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: An analysis of 3,891 ablations in 2,614 patients. Oncology 2007;72:72-5 (Pubitemid 350256668)
56. Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al. Assessment of ablative margin by enhanced magnetic resonance imaging after radiofrequency ablation for hepatocelluar carcinoma. Eur J Radiol 2012;81:2730-6
57. Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, et al. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: Comparison with enhanced CT. Br J Radiology 2012;85:745-52
58. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: A proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 2011;46:1418-26
59. Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al. Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression. J Gastroenterol 2013. doi 10.1007/s00535-012-0747-0
60. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection. Radiology 1999;210: 655-61 (Pubitemid 29124024)
61. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer 1991;68:1524-30
62. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40: 1352-60 (Pubitemid 39657009)
63. Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA, et al. Percutaneous radiofrequency tissue ablation: Does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 1998;9:101-11 (Pubitemid 28049697)
64. Goldberg SN. Radio frequency tumor ablation: Principles and techniques. Eur J Ultrasound 2001;13:129-47 (Pubitemid 32463283)
65. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: Comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223:331-7 (Pubitemid 34454307)
66. Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: A retrospective comparative study. J Gastroenterol 2005;40:1054-60 (Pubitemid 43055290)
67. Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, et al. Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: A retrospective comparative study. Hepatogastroenterology 2007;54:985-9 (Pubitemid 47013888)
68. Livraghi T, Meloni F, Solbiati L, Zanus G; Collaborative Italian Group using AMICA system. Complications of microwave ablation for liver tumors: Results of a multicenter study. Cardiovasc Intervent Radiol 2012;35:868-74
69. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: Influence of hepatic vein size on heatsink effect in a porcine model. J Vasc Interv Radiol 2008;19: 1087-92
70. Liu FY, Yu XL, Liang P, Wang Y, Zhou P, Yu J. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. Int J Hyperthermia 2010;26:448-55
71. Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well preserved hepatic function. J Clin Gastroenterol 2005;39: 247-52
72. Montorsi M, Santambrogio R, Bianchi P, Donadon M, Moroni E, Spinelli A, et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: A multivariate analysis. J Gastrointest Surg 2005;9:62-7
73. Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH, Hwang YJ, et al. The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma. Korean J Hepatol 2005;11:59-71
74. Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: Long-term outcomes. HPB (Oxford) 2005;7:214-21 (Pubitemid 41535854)
75. Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al. Surgical resection versus percutaneous thermal ablation for earlystage hepatocellular carcinoma: A randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006;86:801-5
76. Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: Radiofrequency ablation or resectioñ HPB (Oxford) 2007;9: 429-34 (Pubitemid 350215037)
77. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide survey. J Hepatol 2008;49:589-94
78. Guglielmi A, Ruzzenente A, Valdegamberi A, Pachera S, Campagnaro T, D'Onofrio M, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008;12:192-8
79. Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008;12:1521-6
80. Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg 2009;16:359-66
81. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010;10:78
82. Osaki Y, Ueda Y, Marusawa H, Kimura T, Kita R, Nishikawa H, et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: A single center study. J Gastroenterol 2012;47:444-51
83. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306 (Pubitemid 36205926)
84. Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, et al. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013;47:359-66
85. Hasegawa K, Kokudo N, Shiina S, Tateishi R, Makuuchi M. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: Start of a randomized controlled trial (SURF trial). Hepatol Res 2010;40:851-2
86. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, et al. Percutaneous radiofrequency ablation with cooled electrodes combined with hepatic arterial balloon occlusion in hepatocellular carcinoma. J Gastroenterol 2005;40: 171-8 (Pubitemid 40425205)
87. Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol 2009;20:217-24
88. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. JAMA 2008;299:1669-77 (Pubitemid 351519864)
89. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116: 5452-60
90. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. J Clin Oncol 2013;31: 426-32
91. Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2013;25: 187-94
92. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocelluar carcinoma: Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009;252:905-13
93. de Baere T, Bessoud B, Dromain C, Ducreux M, Boige V, Lassau N, et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. Am J Roentgenol 2002;178:53-9 (Pubitemid 34016370)
94. Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, et al. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2012;18:1379-84
95. Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: A prospective randomized trial. Radiology 2007;244:599-607 (Pubitemid 47080894)
96. Kurokohchi K, Watanabe S, Masaki T, Hosomi N, Funaki T, Arima K, et al. Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. Int J Oncol 2002;21:611-5
97. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: A systematic review. Ann Surg 2009;249:20-5
98. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73
99. Sheiman RG, Mullan C, Ahmed M. In vivo determination of a modified heat capacity of small hepatocellular carcinomas prior to radiofrequency ablation: Correlation with adjacent vasculature and tumour recurrence. Int J Hyperthermia 2012;28: 122-31
100. Ogawa T, Kawamoto H, Kobayashi Y, Nakamura S, Miyatake H, Harada R, et al. Prevention of biliary complication in radiofrequency ablation for hepatocellular carcinoma: Cooling effect by endoscopic nasobiliary drainage tube. Eur J Radiol 2010;73: 385-90
101. Zhen ZJ, Lau WY, Wang FJ, Lai EC. Laparoscopic liver resection for hepatocellular carcinoma in the left liver: Pringle maneuver versus tourniquet method. World J Surg 2010;34:314-9
102. Kotoh K, Nakamuta M, Morizono S, Kohjima M, Arimura E, Fukushima M, et al. A multi-step, incremental expansion method for radio frequency ablation: Optimization of the procedure to prevent increases in intra-tumor pressure and to reduce the ablation time. Liver Int 2005;25:542-7 (Pubitemid 40861903)
103. Giorgio A. Percutaneous radiofrequency ablation of hepatocellular carcinoma on cirrhosis: State of the art and future perspectives. Recent Pat Anticancer Drug Discov 2010;5:69-76
104. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Inoue T, et al. Percutaneous ultrasound-guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. J Gastroenterol 2003;38:1066-70 (Pubitemid 38016367)
105. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H. Percutaneous radiofrequency ablation guided by contrastenhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. Am J Roentgenol 2004;182:1224-6 (Pubitemid 38525518)
106. Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg 2006;93:1277-82 (Pubitemid 44547029)
107. Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: Safety and technical efficacy in 143 patients. Eur Radiol 2009;19:2630-40
108. Kitada T, Murakami T, Kuzushita N, Minamitani K, Nakajo K, Osuga K, et al. Effectiveness of real-time virtual sonographyguided radiofrequency ablation treatment for patients with hepatocellular carcinomas. Hepatol Res 2008;38:565-71 (Pubitemid 351622282)
109. Minami Y, Chung H, Kudo M, Kitai S, Takahashi S, Inoue T, et al. Radiofrequency ablation of hepatocellular carcinoma: Value of virtual CT sonography with magnetic navigation. Am J Roentgenol 2008;190:W335-41 (Pubitemid 351798535)
110. Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, et al. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:759-4
111. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78:40-5
112. Dohmen T, Kataoka E, Yamada I, Miura K, Ohshima S, Shibuya T, et al. Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma. Intern Med 2012;51:1-7
113. Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng YL, et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment in vivo. Acta Radiol 2013;54:199-204
114. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011;7:937-45
115. Guo Y, Zhang Y, Klein R, Nijm GM, Sahakian AV, Omary RA, et al. Irreversible electroporation therapy in the liver: Longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res 2010;70:1555-63
116. Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013;12: 233-41
117. Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, et al. Advanced hepatocellular carcinoma: Treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005;235:659-67 (Pubitemid 40571111)
118. Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, et al. High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience. Ann Surg 2011;253:981-7
119. Lu YC, Chen YJ, Yu YR, Lai YH, Cheng JC, Li YF, et al. Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma. Oncol Rep 2012;28:21-6
120. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Kim YS, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007;102:2164-70 (Pubitemid 47493842)
121. Patriciu A, Awad M, Solomon SB, Choti M, Mazilu D, Kavoussi L, et al. Robotic assisted radio-frequency ablation of liver tumors: Randomized patient study. Med Image Comput Comput Assist Interv 2005;8:526-33 (Pubitemid 43828405)
122. Poggi G, Montagna B, DI Cesare P, Riva G, Bernardo G, Mazzucco M, et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: Preliminary results. Anticancer Res 2013;33:1221-7
123. Lee SM, Won JY, Lee DY, Lee KH, Lee KS, Paik YH, et al. Percutaneous cryoablation of small hepatocellular carcinomas using a 17-gauge ultrathin probe. Clin Radiol 2011;66:752-9
124. Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location. Am J Roentgenol 2012; 199:1393-401